ESR1 and breast cancer: In ER + BC, studies from the use of a new generation of anti-androgen drug, Enzalutamide (also known as MDV3100)20, indicate that AR signaling is required for androgen and estrogen-induced tumor cell growth in vitro and in vivo17.